🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7 results for “Biosimilar” Clear

  1. A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer

    Mabxience Research SL

    advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  2. SB11 (Proposed ranibizumab biosimilar)

    Samsung Bioepis NL B.V.

    Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  3. Bevacizumab Biosimilar IBI305

    The First People's Hospital of Lianyungang

    Post-orthotopic Liver Transplantation

    phase 2 small molecule active

    1 trial

  4. A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.

    Laboratorios Tillomed Spain S.L.U

    Chronic spontaneous urticaria, Allergic asthma, Chronic rhinosinusitis with nasal polyps

    phase 1 other active

    1 trial

  5. A RANDOMIZED, DOUBLE-BLIND, THREE-PART, TWO-PERIOD, TWO-SEQUENCE, SINGLE-DOSE, CROSS-OVER STUDY TO COMPARE THE PHARMACOKINETICS (PK), SAFETY AND IMMUNOGENICITY PROFILE OF MB04 (PROPOSED ETANERCEPT BIOSIMILAR), EU-SOURCED ENBREL® AND US-LICENSED ENBREL® IN HEALTHY MALE VOLUNTEERS.

    Mabxience Research SL

    Not applicable, Healthy Volunteers

    phase 1 other active

    1 trial

  6. Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants

    Lacuna Pharma Pty Ltd

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    phase 1 other active

    1 trial

  7. Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar

    The University of Hong Kong

    Recurrent Ovarian Carcinoma

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources